- Microbix (MBX) has received a binding C$4.7M follow-on order for its viral transport medium
- The medium, known as DxTM, is a sample-collection device for PCR-based testing for viruses that cause COVID-19
- The order stems from a procurement authority representing the Province of Ontario
- Microbix Biosystems develops proprietary biological technology solutions for human health and wellbeing
- Microbix (MBX) is up by 2.43 per cent and is currently trading at $0.84 per share
Microbix (MBX) has received a binding C$4.7M follow-on order for its viral transport medium.
The medium, known as DxTM, is a sample-collection device for PCR-based testing for viruses that cause COVID-19.
The order stems from a procurement authority representing the Province of Ontario.
The company expects to register $1.75M in revenue from the order in Q1 2022 with deliveries occurring across Q2 and Q3 of 2022.
It is currently scaling its production of DxTM through full automation of its filling, capping and labelling processes, with implementation at its third Mississauga site set for spring 2022.
Microbix Biosystems develops proprietary biological technology solutions for human health and wellbeing.
Microbix (MBX) is up by 2.43 per cent and is currently trading at $0.84 per share as of 9:30 am EST.
